Related references
Note: Only part of the references are listed.Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C
Tommaso Maria Manzia et al.
TRANSPLANT INTERNATIONAL (2011)
Azathioprine in Liver Transplantation: A Reevaluation of Its Use and a Comparison with Mycophenolate Mofetil
G. Germani et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients
A. Kornberg et al.
TRANSPLANT INFECTIOUS DISEASE (2007)
Prognostic factors for hepatitis C recurrence in patients undergoing orthotopic liver transplantation
Francisco Sanchez-Bueno et al.
TRANSPLANT IMMUNOLOGY (2006)
MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: Impact on histological course
M Bahra et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation
A Kornberg et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2005)
A model to predict severe HCV-related disease following liver transplantation
M Berenguer et al.
HEPATOLOGY (2003)
Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil
CG Fasola et al.
TRANSPLANTATION PROCEEDINGS (2002)
Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients
M Berenguer et al.
HEPATOLOGY (2002)
Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation
M Berenguer et al.
HEPATOLOGY (2000)
Share Paper
